Univariate survival analyses of 200 NHL patients
| Factor . | 5-year survival (%) . | P . |
|---|---|---|
| IPI | ||
| ≤1 | 74 | <.0001 |
| >1 | 30 | |
| Age at diagnosis (y) | ||
| ≤60 | 60 | <.0001 |
| >60 | 39 | |
| WHO performance status | ||
| 0-1 | 60 | <.0001 |
| 2-4 | 21 | |
| Ann Arbor stage | ||
| I-II | 64 | <.0001 |
| III-IV | 37 | |
| Serum LDH at diagnosis | ||
| Normal | 64 | <.0001 |
| Abnormal | 28 | |
| Presence of B symptoms | ||
| No | 60 | <.0001 |
| Yes | 25 | |
| Histologic grade | ||
| Low | 68 | .0028 |
| Intermediate or high | 49 | |
| No. extranodal sites | ||
| 0-1 | 56 | .0064 |
| >1 | 28 | |
| Serum VEGF at diagnosis | ||
| <462 pg/mL | 61 | <.0001 |
| ≥462 pg/mL (highest quartile) | 31 | |
| Serum bFGF at diagnosis | ||
| <5.5 pg/mL | 59 | .0058 |
| ≥5.5 pg/mL (highest quartile) | 38 | |
| Serum VEGF and bFGF at diagnosis | ||
| both < highest quartile | 64 | <.0001 |
| both within highest quartile | 21 |
| Factor . | 5-year survival (%) . | P . |
|---|---|---|
| IPI | ||
| ≤1 | 74 | <.0001 |
| >1 | 30 | |
| Age at diagnosis (y) | ||
| ≤60 | 60 | <.0001 |
| >60 | 39 | |
| WHO performance status | ||
| 0-1 | 60 | <.0001 |
| 2-4 | 21 | |
| Ann Arbor stage | ||
| I-II | 64 | <.0001 |
| III-IV | 37 | |
| Serum LDH at diagnosis | ||
| Normal | 64 | <.0001 |
| Abnormal | 28 | |
| Presence of B symptoms | ||
| No | 60 | <.0001 |
| Yes | 25 | |
| Histologic grade | ||
| Low | 68 | .0028 |
| Intermediate or high | 49 | |
| No. extranodal sites | ||
| 0-1 | 56 | .0064 |
| >1 | 28 | |
| Serum VEGF at diagnosis | ||
| <462 pg/mL | 61 | <.0001 |
| ≥462 pg/mL (highest quartile) | 31 | |
| Serum bFGF at diagnosis | ||
| <5.5 pg/mL | 59 | .0058 |
| ≥5.5 pg/mL (highest quartile) | 38 | |
| Serum VEGF and bFGF at diagnosis | ||
| both < highest quartile | 64 | <.0001 |
| both within highest quartile | 21 |
Cumulative survival from the diagnosis was computed using the product-limit method. The log rank test was used to compare the different groups.